Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 12, 2026

Montauk Renewables Q4 Earnings Call Highlights

View original at finance.yahoo.com
Montauk Renewables Q4 Earnings Call Highlights Montauk Renewables logo Key Points Operations & development: Montauk grew RNG production in 2025 (the Pico facility was ~31.8% higher year-over-year), completed a second processing unit at Apex, and is commissioning the Turkey, NC facility with first-phase capital of about…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • GreenWave is designed to address limited RNG utilization capacity for transportation by providing third-party RNG volumes access to exclusive, unique, and proprietary transportation pathways

    60% confidence
  • The earn-out related to Pico acquisition was settled in December 2025 with a $4 million payment, following a $0.2 million payment made in July 2025

    60% confidence
  • 2025 EBITDA was pressured by non-capitalizable Turkey development costs without corresponding production and revenue

    60% confidence
  • 2025 RNG production from the expanded, redesigned Pico facility was approximately 31.8% higher than the prior year

    60% confidence
  • The company does not provide guidance on market prices for environmental attributes, including D3 RINs

    60% confidence
  • The company is evaluating additional development expansion opportunities to process available feedstock volumes at Pico

    60% confidence
  • At first-phase capacity of Turkey facility, the company anticipates being able to process feedstock from about 400,000 to 450,000 hog spaces, equating to about 35,000 tons of annual waste collection

    60% confidence
  • Blue Granite development project local utility is no longer accepting RNG into its distribution system; Montauk has paused development while reviewing alternatives

    60% confidence
  • Certain 2025 non-cash stock-based compensation adjustments were not expected to repeat in 2026

    60% confidence
  • The company refinanced its existing debt with a new lender on March 9, 2026

    60% confidence
  • Montauk grew RNG production in 2025 despite having sold one RNG facility in 2024

    60% confidence
  • Montauk's profitability remains highly dependent on the market price of environmental attributes, including RINs

    60% confidence
  • Compliance obligations for North Carolina utilities that filed the September 2025 joint motion continue to increase through 2029

    60% confidence
  • The company expects first-phase capital investment of approximately $200 million at Turkey facility and expects production and revenue generation to commence in April 2026

    60% confidence
  • Because the company self-markets a significant portion of its RINs, decisions about whether to commit transfers during a period can impact reported revenue and operating profit

    60% confidence
  • The company did not record impairments related to its assessment of future cash flows

    60% confidence
  • At Pico project, inlet feedstock averaged about 458,000 gallons per day, about 17% above the contractual minimum

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Montauk Renewables Q4 Earnings Call Highlights — Source | Via News | Via News